SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision
clinical 1,723 words KG: LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD
Contents

LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

Wikipedia

Related Hypotheses (46)

Phase-Separated Organelle Targeting
Score: 0.73Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.72Stress Granule Phase Separation Modulators
Score: 0.72Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71Orexin-Microglia Modulation Therapy
Score: 0.71TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71Lysosomal Enzyme Trafficking Correction
Score: 0.71Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70Lysosomal Calcium Channel Modulation Therapy
Score: 0.70Complement C1q Mimetic Decoy Therapy
Score: 0.69Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69Ganglioside Rebalancing Therapy
Score: 0.69Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69R-Loop Resolution Enhancement Therapy
Score: 0.68Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.67Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67Arginine Methylation Enhancement Therapy
Score: 0.65Glial Glycocalyx Remodeling Therapy
Score: 0.65HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.65
← Prevpg 2/3Next →

Related Analyses (22)

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completedRNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archivedSynaptic pruning by microglia in early AD
neurodegeneration · archivedMitochondrial transfer between astrocytes and neurons
neurodegeneration · archivedEpigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived

Related Experiments (13)

Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40ApoE4 Function in Alzheimer's Disease
validation · proposed · Score: 0.40

See Also (15)

Neurodegeneration
disease · Pages share 12 hypothesesAPOE contributes to Alzheimer's disease by regulating b
hypothesis · Pages share 11 hypothesesBEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 11 hypothesesAPOE4 (Apolipoprotein E4)
disease · Pages share 10 hypothesesCALB1 (Calbindin 1)
gene · Pages share 10 hypotheses

Knowledge Graph (3 edges)

LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD references LDLR
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD references LRP1
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD references APOE

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.
SciDEX — scidex.ai — Dashboard | Atlas